



(11) **EP 3 949 967 A8**

(12) **CORRECTED EUROPEAN PATENT APPLICATION**
published in accordance with Art. 153(4) EPC

(15) Correction information:
Corrected version no 1 (W1 A1)
Corrections, see
Bibliography INID code(s) 71

(48) Corrigendum issued on:
07.09.2022 Bulletin 2022/36

(43) Date of publication:
09.02.2022 Bulletin 2022/06

(21) Application number: **20795435.5**

(22) Date of filing: **23.04.2020**

(51) International Patent Classification (IPC):
A61K 31/519^(2006.01) A61K 9/20^(2006.01)
A61P 31/12^(2006.01)

(52) Cooperative Patent Classification (CPC):
A61P 31/12; A61K 9/2054; A61K 9/2059;
A61K 31/519

(86) International application number:
PCT/CN2020/086301

(87) International publication number:
WO 2020/216274 (29.10.2020 Gazette 2020/44)

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **23.04.2019 CN 201910326899**

(71) Applicant: **CHIA TAI TIANQING**
PHARMACEUTICAL GROUP CO., LTD.
Lianyungang,
Jiangsu 222062 (CN)

(72) Inventors:
• **JING, Jianghui**
Lianyungang City, Jiangsu 222062 (CN)
• **DONG, Lihui**
Lianyungang City, Jiangsu 222062 (CN)
• **XU, Yi**
Lianyungang City, Jiangsu 222062 (CN)
• **LI, Xinlu**
Lianyungang City, Jiangsu 222062 (CN)

- **LU, Xifeng**
Lianyungang City, Jiangsu 222062 (CN)
- **WANG, Shang**
Lianyungang City, Jiangsu 222062 (CN)
- **ZANG, Haishan**
Lianyungang City, Jiangsu 222062 (CN)
- **LI, Min**
Lianyungang City, Jiangsu 222062 (CN)
- **CHEN, Zhilin**
Lianyungang City, Jiangsu 222062 (CN)
- **ZHAO, Xiandong**
Lianyungang City, Jiangsu 222062 (CN)
- **SUN, Peng**
Lianyungang City, Jiangsu 222062 (CN)

(74) Representative: **Thoma, Michael**
Lorenz Seidler Gossel
Rechtsanwälte Patentanwälte
Partnerschaft mbB
Widenmayerstraße 23
80538 München (DE)

(54) **SOLID PHARMACEUTICAL COMPOSITION COMPRISING TLR7 AGONIST**

(57) A solid pharmaceutical composition comprising a TLR7 agonist 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)benzyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine, a preparation method therefor, and an medical application thereof. The solid pharmaceutical composition has excellent stability and dissolution properties.

EP 3 949 967 A8